The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story
Tag Archive | "Cephalon"
Partnering Agreements with Cephalon
Posted on 06 June 2012
This report provides all the information you require to better understand Cephalon and its partnering interests and activities over the past seven years. Read the full story
Cephalon: Company Profile
Posted on 02 February 2012
Cephalon, Inc. is an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd, is , is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story
Acino to acquire Cephalon’s Middle East and North Africa business
Posted on 14 October 2011
Acino will acquire Cephalon’s combined Middle East and African business for a total consideration of approximately EUR 80 million. Read the full story
Cephalon to pay Teva $275m if deal cancelled
Posted on 04 May 2011
Teva states in a notice to the US Securities and Exchange Commission (SEC) that if Cephalon cancels its acquisition by Teva, it will pay a fine of 4% of the $6.8 billion deal - or $275 million. Read the full story
Teva outbids Valeant to acquire Cephalon
Posted on 03 May 2011
Cephalon have accepted a bid from Teva which values the company at $6.8 billion, some $1.1 billion more than the Valeant offer of several weeks ago. Read the full story
Valeant moves on to new M&A targets
Posted on 02 May 2011
Now that Teva Pharmaceutical Industries has snatched Cephalon, what's next for would-be suitor Valeant Pharmaceuticals? Read the full story
Acquisition agreement for Cephalon
Posted on 02 May 2011
Definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion Read the full story
Current Agreements Deals Update – April 2011
Posted on 10 April 2011
Welcome to the April 2011 edition of Current Agreements Deals Update. Read the full story
Valeant bid re-focusses pharma M&A interest
Posted on 07 April 2011
Valeant Pharmaceuticals' $5.7 billion bid for Cephalon may spawn a series of copycat deals, Reuters reports... Read the full story
